News and industry insights on Contract development and manufacturing services for chemicals, particularly in pharmaceuticals and specialties.
WuXi Biologics received ANVISA GMP certification for MFG2, DP1 and DPPC and its Suzhou Biosafety Testing Center gained a fourth EMA GMP certificate. South Korea’s MFDS also certified MFG5, DP2 and DPPC, while DP15 at Fengxian reached GMP release. Capacity advanced with the modular Drug Product facility at the Singapore CRDMO Hub topping out.
AGC Biologics broadened offerings via a strategic partnership with Pyramid Pharma Services to add U.S. sterile fill‑finish, alongside ANVISA GMP certification for the Seattle site. New work included KTP‑001 for Teikoku Pharma and NN4101 for retinal disease, and it supported U.S./EU approvals of the ex vivo gene therapy Waskyra.
Process technologies advanced: Asahi Kasei’s FO–MD system began manufacturing trials at Peptistar; Asahi Kasei Life Science licensed The Noguchi Institute’s precision ADC technology; and WuXi Biologics launched the PatroLab digital twin platform. Toray introduced a high‑efficiency separation membrane module, and WACKER rolled out Contract Research Services for nucleic‑acid medicines.
Evonik agreed to sell selected Hanau pharmaceutical‑ingredient assets to ProChem, invested €80m in downstream bioprocessing in Slovakia, and opened the Open Pharma Lab in Yokohama with Higuchi. The EIB financed Orano Med’s Advanced Thorium Extraction Facility and, with partners, Biovac’s end‑to‑end vaccine plant. Meanwhile, CELLforCURE sought a buyer amid weaker cell‑gene funding.
Top 5 companies involved as owner and/or investor in current and planned CDMO projects:
Sandoz , Lonza , Merck , Novo Nordisk , and Biovac .
